Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Currency-adjusted sales revenue up 2.8%; order intake in constant currencies up 0.9%; operating result (EBITA) at EUR40.6 million; EBITA margin: 8.9%; financing on a solid, broad-based ...

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Figures for the First Nine Months of 2008 28.10.2008 To ensure the best possible comparability, the figures of the year-earlier period are presented on a pro forma basis and adjusted for non-operating effects. For the nine-month period, the Sartorius Group achieved a currency-adjusted gain of 2.8%. Consolidated sales revenue in the reporting currency is at EUR453.4 million (2007 pro forma: EUR458.8 mn; -1.2%). The Biotechnology Division's sales revenue was up a currency-adjusted 1.0%, but edged down 3.0% in the reporting currency, from EUR281.8 mn to EUR273.3 mn. The Mechatronics Division´s revenue grew 1.7% (currency-adjusted: +5.5%) from EUR177.0 mn to EUR180.0 mn. The Group´s order intake eased 3.0% (currency-adjusted: +0.9%) from EUR468.2 mn to EUR454.0 mn (Biotechnology: -5.1%, currency-adjusted: -1.1%; Mechatronics: +0.2%, currency-adjusted: +3.9%. Operating earnings (EBITA) are at EUR40.6 million relative to EUR46.9 million a year ago (Biotechnology: EUR29.1 mn vs. EUR35.2 mn in 2007; Mechatronics: EUR11.4 mn vs. EUR11.7 mn in 2007). Currency effects and the higher R&D costs budgeted weighed down on earnings. Particularly impacted by the higher euro-zone base interest rate, consolidated net profit after minority interest totals EUR10.0 mn (2007: EUR16.2 mn). Earnings per share, excluding the two non-cash items of amortization and interest for the share price warrants granted, are accordingly at EUR0.80 (2007: EUR1.11). In view of the increasingly difficult global economic conditions, we currently do not consider it possible to make an accurate and reliable quantitative forecast of further business development. We continue to see ourselves well-positioned in our markets, but do not expect to reach the full-year targets we announced on the basis of our first-half 2008 figures, because of the gloomy economic environment. However, we do anticipate a robust operating result for the fourth quarter as well. in millions of EUR (unless 9-month 2008 9-month 2007 Change otherwise specified) pro forma in % Sartorius Group Sales revenue 453.4 458.8 -1.2 (+2.8) Order intake 454.0 468.2 -3.0 (+0.9) EBITA 1) 40.6 46.9 -13.6 Net profit 1)2) 13.7 18.9 -27.8 Earnings per share 1)2) in EUR 0.80 1.11 Biotechnology Division Sales revenue 273.3 281.8 -3.0 (+1.0) Order intake 269.3 283.8 -5.1 (-1.1) EBITA 1) 29.1 35.2 -17.2 Mechatronics Division Sales revenue 180.0 177.0 +1.7 (+5.5) Order intake 184.8 184.5 +0.2 (+3.9) EBITA 1) 11.4 11.7 -2.8 in parentheses: currency-adjusted 1) For 2007 adjusted for non-operating effects 2) Excluding non-cash amortization and, for 2008, additionally excluding non-cash interest expenses for share price warrants Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the nine-month results for Sartorius with analysts and investors in a teleconference today (Oct. 28, 2008) at 3 p.m. CET. You may dial into this teleconference starting at 2:45 p.m. CET at the following numbers: Germany: +49 (0) 69 2222 2220; France: +33 (0) 1 70 99 42 82; UK: +44 (0) 20 7138 0839; USA: +1 718 354 1362 The dial-in code is: 4944170. To view the webcast, log ontohttp://www.sartorius.com end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Sartorius AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Andreas Wiederhold Treasury & Investor Relations Telefon: +49 (0)551 308-1668 E-Mail: andreas.wiederhold@sartorius.com Branche: Biotechnology ISIN: DE0007165607 WKN: 716560 Index: CDAX, Prime All Share, Technologie All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade

Das könnte Sie auch interessieren: